Skip Ribbon Commands
Skip to main content


Biotie has a broad pipeline of novel, potentially first or best-in class products in clinical development

Our focus is on generating innovative, clinically differentiated medicines for the treatment of neurodegenerative and psychiatric diseases based on strong scientific, medical and commercial rationale. We aim to advance our products through Phase 2 before seeking a partnership with large pharma or biotech for late stage development and commercialization.   In situations where we believe we can be competitive, e.g. for specialty or orphan indications, we will progress our pipeline internally to registration, approval and market.  We have a dedicated team of scientists, in Europe and the US, with the drive and enthusiasm to deliver new medicines to patients.



Phase 1 ​Phase 2 Phase 3 Launched
Selincro​ (nalmefene) -
alcohol dependence.
Tozadenant (SYN115) - Parkinson's disease.

NRL-1 -
Acute Repetitive Epileptic Seizures (option).
Nepicastat (SYN117) -
cocaine dependence.

Phase 2 ongoing
SYN120 -
Alzheimer's disease and other
cognitive disorders.
BTT-1023 (VAP-1 antibody) -


Updated 24 March, 2014